Core sleep measures and resources will help
transform sleep research and care to advance the treatment of
multiple disease areas
BOSTON, April 24,
2024 /PRNewswire/ -- Today, the Digital Health
Measurement Collaborative Community (DATAcc) by the Digital
Medicine Society (DiMe) released a core set of digital
measures and resources for sleep. Together, these will increase the
availability of high-quality, standardized, and transparent sleep
assessments in a natural environment and transform research and
care to advance overall population health. The core digital
measures set and resources were developed by a cross-disciplinary
group of experts designed to maintain broad applicability across
research, care, and multiple disease areas.
As a community, we have just scratched the surface of sleep
measurement's potential in identifying and treating a wide range of
diseases and health conditions. Better sleep means better health,
and disrupted sleep can indicate or cause chronic conditions
ranging from primary sleep disorders to mental health conditions to
Parkinson's Disease to Women's health to cardiac conditions and
more. Today, the most common way to measure sleep requires the
evaluation of a patient in a sleep lab where the environment is
unfamiliar, the equipment is uncomfortable, and the routine is
anything but normal. Using DATAcc's new core digital measures
allows us to move measurement to the routine and comfort of one's
bedroom, resulting in greater access to measurement, lower costs of
studies, and more representative readings due to the natural sleep
environment - meaning better interventions and remedies for
all.
"Sleep science is key to unlocking new drugs and therapies
across many disease areas and improving lives, but defining
digitally derived measures of sleep requires a significant amount
of measurement science, as it is a complex and challenging task,"
said DiMe CEO Jennifer Goldsack.
"The core digital measures of sleep and accompanying resources now
make it more accessible than ever before to incorporate sleep data
into trials and care plans where sleep was previously inaccessible.
With these resources, the clinical and research communities can use
the new, digital generation of low-friction tools to improve our
understanding of the relationship between sleep, health, and
disease; improve the way we care for people with all manner of
sleep disorders; and develop new therapies based on a deeper
knowledge of previously unidentifiable connections between sleep
and disease areas."
"DiMe Sleep Project provided Bayer with a unique opportunity to
delve deeply into this crucial aspect of human health and the
ramifications of poor sleep on patients with numerous diseases,"
added Michael Kremliovsky. Sr. Director of Medical Devices &
eHealth, Bayer. "Collaboration among clinicians, government
agencies, technology providers, and our peers in the pharmaceutical
industry is instrumental in establishing a shared framework for
advancing innovative clinical measures of sleep. Our goal is to
accelerate the translation of this research into tangible health
benefits for patients and to transform sleep research and patient
care."
Participating in the development of the Core Measures of Sleep
and accompanying resources were project partners: Bayer,
Boston University, Defense Innovation
Unit, Duke University, Eli Lilly &
Company, GSK, Jazz Pharmaceuticals, National Sleep Foundation,
NextSense, Sage Bionetworks, Sage Therapeutics, Takeda, TC
Demiroglu Bilim University, UZ Leuven, US Department of Veterans
Affairs and digital solutions collaborators: Activinsights, Beacon
Biosignals, Biostrap, Byteflies, Dreem, Google, Ouraring, Primasum,
Sleep Number, Softmatter, TNO, and VivoSense.
DATAcc by DiMe continues to drive the industry on digital
endpoints. In addition to the core measures and over 15 new
resources, the project team also added sleep digital measurement
products to the Library of Digital Measurement Products. This
open-access repository now serves as a one-stop-shop for
high-quality digital clinical measures, measurement tools, and
datasets to use in research and care for four key areas: sleep,
Alzheimer's disease and related dementias (ADRD), physical activity
(PA), and Parkinson's disease (PD).
Additionally, a recent study conducted in partnership with Tufts
Center for the Study of Drug Development and leaders from J&J,
Roche and Genentech, UCB, Bayer, Takeda, and Mindmed shows evidence
of significant cost reductions and financial benefits tied to
leveraging digital endpoints in trials. DiMe will launch a new
project to support innovators across the field to invest in digital
endpoints and advance their broad adoption and scale in clinical
research. To learn more, click here.
About the Digital Medicine Society: DiMe is a global
non-profit and the professional home for all members of the digital
medicine community. Together, we tackle the toughest digital
medicine challenges, develop clinical-quality resources on a
technology timeline, and deliver these actionable resources to the
field via open-source channels and educational programs.
About DATAcc by DiMe: The Digital Health Measurement
Collaborative Community (DATAcc) by the Digital Medicine
Society (DiMe) is a collaborative community with the
FDA's Center for Devices and Radiological Health. We provide a
forum for collaboration where partners and experts from across the
digital health field work to advance the use of digital health
measures in research to improve lives.
Media Contact: Carla
English, press@dimesociety.org
View original content to download
multimedia:https://www.prnewswire.com/news-releases/datacc-by-dime-launches-core-measures-for-sleep-302124920.html
SOURCE Digital Medicine Society (DiMe)